Decoy Therapeutics
DCOY
3 hedge funds and large institutions have $25M invested in Decoy Therapeutics in 2018 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
16% more capital invested
Capital invested by funds: $21.7M → $25M (+$3.38M)
0% more funds holding
Funds holding: 3 → 3 (0)
0% more ownership
Funds ownership: 0% → 0% (0%)
99% less call options, than puts
Call options by funds: $1K | Put options by funds: $83K
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.34M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$19K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$7K |
DCOY Hedge Fund Activity: Q1 2018 in Review
3 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q1 2018, worth a combined $25M — up 16% from $21.7M a quarter earlier.
Fund positioning in DCOY was balanced in Q1 2018: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Sphera Funds Management, cutting an estimated $4.34M.
- 3 institutional investors held Decoy Therapeutics (DCOY) as of Q1 2018, unchanged from Q4 2017.
- Funds reported $25M of Decoy Therapeutics stock for Q1 2018, up 16% quarter-over-quarter.
- 0 funds opened new Decoy Therapeutics positions in Q1 2018 and 0 closed out.
- The largest Decoy Therapeutics seller in Q1 2018 was Sphera Funds Management, an estimated $4.34M sold.
Based on aggregated 13F filings for Q1 2018.